Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Antibodies Derived from Llamas Neutralize SARS-CoV-2 Virus

By HospiMedica International staff writers
Posted on 15 Jul 2020
Antibodies derived from llamas have been shown to neutralize the SARS-CoV-2 virus in lab tests, raising hopes that they could eventually be developed as a treatment for patients with severe COVID-19.

Researchers from the University of Oxford (Oxford, UK) in collaboration with the Rosalind Franklin Institute, Oxford University, Diamond Light Source and Public Health England engineered their new antibodies, known as nanobodies due to their small size, using a collection of antibodies taken from llama blood cells. More...
Llamas, camels and alpacas naturally produce quantities of small antibodies with a simpler structure that can be turned into nanobodies. The researchers have demonstrated that the nanobodies bind tightly to the spike protein of the SARS-CoV-2 virus, blocking it from entering human cells and stopping infection. Using advanced imaging with X-rays and electrons, the team also identified that the nanobodies bind to the spike protein in a new and different way than the other antibodies that have been already discovered.

The team started from a lab-based library of llama antibodies and is now screening antibodies from Fifi, one of the ‘Franklin llamas’ based at the University of Reading, taken after she was immunized with harmless purified virus proteins. The researchers are investigating preliminary results which show that Fifi’s immune system has produced different antibodies from those already identified, which will enable cocktails of nanobodies to be tested against the virus.

“These nanobodies have the potential to be used in a similar way to convalescent serum, effectively stopping progression of the virus in patients who are ill,” said Professor James Naismith, Director of The Rosalind Franklin Institute and Professor of Structural Biology at Oxford University. “We were able to combine one of the nanobodies with a human antibody and show the combination was even more powerful than either alone. Combinations are particularly useful since the virus has to change multiple things at the same time to escape; this is very hard for the virus to do. The nanobodies also have potential as a powerful diagnostic.”

Related Links:
University of Oxford


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.